Eton Pharmaceuticals (ETON) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Eton Pharmaceuticals (ETON) do?
Eton Pharmaceuticals Inc (ETON) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Acquires, commercializes, and develops prescription medications for rare pediatric diseases. Sells treatments through specialized distribution networks and direct hospital sales. It is worth $1.77B on the market and sold $141.02M over the last year.
- Market cap
- $1.77B
- P/E ratio
- 40.7×
- Annual sales
- $141.02M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 12, 2026
Brands and businesses behind ETON
- Increlex: An injectable therapy for severe growth hormone deficiency in children that generates revenue through specialty prescription sales.
- Hemangiol: An oral liquid treatment for proliferating infantile hemangioma that earns revenue through pediatric hospital and specialty pharmacy sales.
- Alkindi Sprinkle: An oral granule hydrocortisone replacement for pediatric adrenal insufficiency that earns revenue via prescription sales.
- Libervant: A prescription buccal film for pediatric seizure clusters that generates revenue through pharmacy fulfillment.
ETON’s flags, in plain English
Each flag is a number from Eton Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Fat Margins
Profit margin of 35.4%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Earns Its Keep
Earns 90.6% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Capital Works Hard
Earns 50.3% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.
Priced for Perfection
Priced at 40.7 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about ETON
How big is Eton Pharmaceuticals?
Eton Pharmaceuticals’ market cap is $1.77B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $141.02M: what customers paid the company over the last year, before any costs.
What is ETON’s P/E ratio?
ETON’s P/E ratio is 40.7×. Investors pay about 40.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ETON?
The business relies on third-party contract manufacturers and packaging partners to produce all of its commercial drug supplies. That is one risk on Eton Pharmaceuticals’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Eton Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ETON’s filings on SEC.gov. The Margin Monkey is research, not advice.
